TESARO,Inc. (NASDAQ:TSRO) Files An 8-K Other Events

ME Staff 8-k
-
0
TESARO,Inc. (NASDAQ:TSRO) Files An 8-K Other Events

TESARO,Inc. (NASDAQ:TSRO) Files An 8-K Other Events
Item 8.01 Other Events.

On December4, 2018, TESARO,Inc. (the “Company”) issued a press release to the terms of the Indenture, dated as of September29, 2014, between the Company and U.S. Bank National Association, as trustee (the “Trustee”) (as supplemented by that First Supplemental Indenture to the Indenture, dated as of September29, 2014, between the Company and the Trustee, the “Indenture”), announcing an anticipated “Make-Whole Adjustment Event” (as such term is defined in the Indenture) that will occur as a result of completion of the proposed transactions contemplated by the Agreement and Plan of Merger, dated December3, 2018, by and between the Company, GlaxoSmithKline plc (“GSK”) and Adriatic Acquisition Corporation, an indirect wholly-owned subsidiary of GSK. A copy of the press release is attached as Exhibit99.1 hereto and incorporated herein by reference.

Section9 — Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


TESARO, Inc. Exhibit
EX-99.1 2 a18-41016_5ex99d1.htm EX-99.1 Exhibit 99.1     TESARO,…
To view the full exhibit click here

About TESARO,Inc. (NASDAQ:TSRO)

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform. It offers VARUBI (rolapitant), which is an oral substance P/neurokinin 1 (NK-1) receptor antagonist for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. It is developing IV formulation of rolapitant, which has completed various Phase 1 clinical trials. Its niraparib is an orally active and poly (ADP-ribose) polymerase (PARP) inhibitor. Its immuno-oncology platform has immuno-oncology programs, which include TSR-022 and TSR-042.